The global cell and gene therapy market share was estimated to be worth $4.32 billion in 2021, and it is expected to reach $54.19 billion by 2030, expanding at a CAGR of 32.45% from 2021 to 2030.
Cell therapy refers to the process of administering live cells to patients with the purpose of treating various diseases. Both autologous and allogeneic cells, which can be produced from stem cells found in places like bone marrow, can serve as the source of the cell. The treatment of bone marrow transplant patients often involves stem cell therapy. In the context of medical practice, "gene therapy" refers to any procedure that modifies, deletes, or otherwise alters a patient's genetic code. In addition, it can change the way a person's genes are expressed or fix genes that aren't functioning properly. In this treatment, nucleic acid (DNA or RNA) is given to the patient together with carriers that are referred to as vectors.
The majority of pharmaceutical companies continue to make significant investments in the development of new medications and equipment. The pharmaceutical business, in particular, is heavily invested in research and development. Pharmaceutical firms spend on research and development in order to bring high-quality, innovative goods to market. The trend implies that major pharma companies are enhancing their R&D efficiency by investing heavily in R&D in order to obtain long-term returns on their investment, as well as through collaborating on R&D.
Cell therapy targets various diseases at the cellular level, such as by restoring a certain cell population or by using cells as carriers of the therapeutic carriers, whereas gene therapy aims to influence the course of various genetic and acquired disorders at the genetic level. Gene therapies also aim to treat inherited disorders as well as acquired ones. It is anticipated that the high incidence of cardiovascular illness would accelerate demand for cell and gene therapy, which will in turn fuel the growth of the market.
Clinical tests are an essential component of medical research, and they provide assistance to the pharmaceutical and biopharmaceutical industries in their efforts to develop and bring innovative cell and gene treatments to market. Due to the increased need for innovative medications to satisfy unmet medical requirements, there has been a worldwide increase in the number of clinical trials that have been conducted during the past several years.
The North American cell and gene therapy market is driven by the region's high economic position as well as the region's high spending on healthcare services. Sponsorship and financial support for cell and gene therapy products come mostly from national health institutions, companies, academic institutes, and hospitals respectively.
Major players in the cell & gene therapy market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Charles River Laboratories (US), Lonza (Switzerland), Catalent (US), WuXi AppTec (China), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK).
In 2021, Charles River Laboratories expanded its cell and gene therapy manufacturing capabilities by purchasing Cognate BioServices, a contract manufacturing organization (CMO) specializing in cell and gene therapy.
Thermo Fisher Scientific paid roughly USD 859.7 million to buy Henogen S.A. in 2021. Henogen S.A. was the viral vector production company that Novasep operated in Belgium. Through this purchase, it will be able to strengthen its position in the manufacturing therapeutic market for cell and gene therapies.
In 2019, Thermo Fisher Scientific spent $1.7 billion to purchase Brammer Bio, a firm whose primary business was the production of viral vectors for use in gene and cell treatments.